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Th  erapy for rheumatoid arthritis (RA) has advanced 
tremendously over the past 10 years. Biologic therapy 
employing recombinant antibodies and receptors has 
become the standard of care. Neutralization of cytokines 
(tumor necrosis factor-alpha and interleukin-6), inhibi-
tion of co-stimulatory pathways (CTLA4Ig), and B-cell 
depletion (anti-CD20) have all been shown to be eﬀ  ective 
therapies. However, each requires parenteral adminis  tra-
tion, is expensive, and may result in undesired side 
eﬀ   ects. Over the last several years, there have been 
intensi ﬁ  ed eﬀ  orts to develop small-molecule inhibitors 
that can be taken orally and that may result in less 
expensive, safer, and more conveniently administered 
therapy. In this issue of Arthritis Research & Th  erapy, 
Chang and colleagues [1] present data demon  strating the 
eﬀ  ectiveness of a selective Bruton tyrosine kinase (Btk) 
inhibitor, PCI-32765, in two experimental models of RA.
Btk was originally identiﬁ   ed as defective in patients 
who had X-linked agammaglobulinemia and who exhi  bi-
ted a profound reduction of B cells. Btk is a non-receptor 
tyrosine kinase within the Tec family of kinases and 
contains six domains: pleckstrin homogy (PH), Btk 
homology, polyproline region, two Src homology (SH2 
and SH3), and a tyrosine kinase. Th   ough originally identi-
ﬁ  ed in B cells (identifying it as a potential B-cell target), it 
has been found more recently in myeloid cells, including 
monocytes, macrophages neutrophils, and mast cells [2]. 
Btk is activated by crosslinking immuno  globulins on the 
surface of B cells and by the ligation of Fc receptors and 
integrins on myeloid cells, mediated through Src kinases, 
including Lyn and Syk [3,4], the latter a promising 
therapeutic target in RA. Src kinase activation of plasma 
membrane-bound (through the PH domain) Btk results 
in tyrosine phosphorylation of tyrosine 551 (in the 
tyrosine kinase domain), which leads to autophosphory-
lation at tyrosine 223 (in the SH3 domain), resulting in 
full kinase activity. Activated Btk drives phosphorylation 
of PLCγ and subsequent PKC activation, which in turn 
results in the calcium ﬂ  ux and the activation of trans  crip-
tion factors, including nuclear factor-kappa-B (NF-κB) 
and NF-AT, regulating the expression down  stream genes 
controlling proliferation, survival, and chemokine and 
cytokine gene expression [2]. PCI-32765, like other Btk 
inhibitors, was designed to inhibit the activation by 
select  ively interacting with an ATP-binding site in the 
tyrosine kinase domain, preventing Btk phos  phorylation 
and activation [5-7].
Adding to their previously published observations in 
collagen-induced arthritis [8], Chang and colleagues [1] 
convincingly demonstrate the therapeutic eﬀ  ectiveness of 
PCI-32765 in collagen-induced arthritis, documenting 
marked reduction of joint swelling, destruction, and 
inﬂ  am  matory mediators. However, their prior publica-
tion demonstrated that the improvement was due in part 
to suppression of the anti-collagen antibody response [8], 
consistent with the results observed with another Btk 
inhibitor [5]. However, suppression of the collagen 
antibody-induced arthritis (CAIA) model, which 
employed anti-collagen antibodies plus the Toll-like 
receptor 4 (TLR4) ligand lipopolysaccharide (LPS), by 
both Btk inhibitors demonstrates an eﬀ  ect beyond just 
suppression of autoantibody production [1,5]. Th  e in 
vitro studies demonstrate the ability to inhibit B-cell 
activation and proliferation and to inhibit activation 
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inability to suppress TLR4 signaling confounds the 
interpretation of the CAIA model, which employs LPS. 
In contrast, other studies have documented a role for Btk 
in macrophage activation through TLR4 [9,10]. Th  e 
ability to suppress TLR signaling might be beneﬁ  cial in 
RA since TLR signaling may contribute to the progres-
sion of RA mediated by endogenous TLR ligands [11].
How might Btk inhibitors, given their eﬀ  ectiveness in 
animal models, ﬁ  t into the armamentarium of therapies 
for RA? Th   at depends on a number of factors. Th  e  ﬁ  rst, 
and most important, is whether success in animal models 
will translate to eﬃ     cacy in human disease. Th  e p38 
mitogen-activated protein (MAP) kinase experience, in 
which a number of compounds that demonstrated 
promising eﬃ   cacy in preclinical animal models failed to 
deliver on that promise in clinical studies in patients with 
RA, taught us a valuable lesson in this regard [12,13]. Th  e 
p38 experi  ence taught us another important lesson as 
well: the ubiquitous nature of the kinase family, and its 
presence in so many diﬀ  erent cell types, increases the 
likelihood of oﬀ  -target  eﬀ   ects of inhibitors of these 
proteins. Th  e similarity of the Btk ATP-binding site to 
other kinase-binding sites makes this concern relevant. 
For some of the p38 MAP kinase inhibitors that advanced 
into clinical trials, this resulted in central nervous system 
eﬀ   ects and elevated liver enzymes that threatened to 
overshadow their modest clinical eﬃ   cacy.
Th   e two kinase inhibitors that have moved farthest into 
clinical development – tofacitinib, a JAK kinase inhibitor, 
and fostamatinib, a Syk kinase inhibitor – have success-
fully bridged the gap between animal models and human 
clinical eﬃ   cacy. Moreover, early evidence suggests that 
they have done so with oﬀ  -target toxicity that is likely to 
be acceptable in light of their clinical eﬃ   cacy. Although 
this is promising, it remains to be seen whether Btk 
inhibitors will meet this promise in patients with RA.
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